However, despite the relevance of NANOG expression in ICB therapy–refractory cancer, the precise mechanism by which NANOG could trigger resistance to ICB therapy, especially through HDAC1-mediated epigenetic reprogramming, is not well understood. This evidence concerns the gene HDAC1 and cancer.